VON WILLEBRAND DISEASE, TYPE 3
Clinical trials for VON WILLEBRAND DISEASE, TYPE 3 explained in plain language.
Never miss a new study
Get alerted when new VON WILLEBRAND DISEASE, TYPE 3 trials appear
Sign up with your email to follow new studies for VON WILLEBRAND DISEASE, TYPE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot aims to stop bleeds in rare blood disorder
Disease control Recruiting nowThis study tests a medicine called emicizumab to prevent bleeding episodes in people with Type 3 von Willebrand disease, a severe inherited bleeding disorder. About 75 participants aged 1 month and older will receive regular injections of emicizumab or continue their current stan…
Matched conditions: VON WILLEBRAND DISEASE, TYPE 3
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 10:27 UTC
-
Could a simple shot replace IV drips for severe bleeding disorder?
Disease control Recruiting nowThis early-stage study tests whether emicizumab (Hemlibra), given as a shot under the skin, can safely prevent bleeding in people with severe von Willebrand disease or combined VWD/hemophilia A. Currently, severe bleeds require IV infusions of clotting factor. The trial enrolls 4…
Matched conditions: VON WILLEBRAND DISEASE, TYPE 3
Phase: PHASE1 • Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois • Aim: Disease control
Last updated May 26, 2026 10:22 UTC
-
New study tracks bleeding episodes and daily life impact in rare bleeding disorder
Knowledge-focused Recruiting nowThis study is for people with Type 3 von Willebrand disease, a rare and severe bleeding disorder. Researchers will watch how often bleeding happens and how it affects daily life while participants continue their usual preventive treatment. The goal is to gather real-world informa…
Matched conditions: VON WILLEBRAND DISEASE, TYPE 3
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated May 26, 2026 10:28 UTC